Aging Medicine
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
G.P. Rossi, V. Sanga, M. Barton
eLife 2020;9:e57278
Heart failure with preserved ejection fraction in women - new clues to causes and treatment
M. Barton, M.R. Meyer
JACC Basic Transl Sci 5, 296-299,2020
Endothelin: 30 years from discovery to therapy
M. Barton, M. Yanagisawa
Hypertension 74, 1232-1265, 2019
Nox1 downreglators: A new class of therapeutics
M. Barton, M.R. Meyer, E.R. Prossnitz
Steroids 152, 108949, 2019
Potential role for Nox1 for endothelin-induced brain capillary vasoconstriction in Alzheimer's disease and dementia
M. Barton, M.R. Meyer, E.R. Prossnitz.
Science eaav9518, 2019
Primum non nocere: Why calcitriol («vitamin» D) hormone therapy is not a magic bullet
M. Barton
Arterioscler Thromb Vasc Biol 39, 117-120, 2019
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: role in disease conditions. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 462-471, 2018
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: general mechanisms. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 451-461, 2018
GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases
M.R. Meyer, M. Barton
J Steroid Biochem Mol Biol 176, 82-87, 2018
GPER mediates functional endothelial aging in renal arteries
M.R. Meyer, T. Rosemann, M. Barton, E.R. Prossnitz.
Pharmacology 100, 188-193, 2017
Obligatory role for GPER in cardiovascular aging and disease
M.R. Meyer, N.C. Fredette, C. Daniel, G. Sharma, K. Amann, J.B. Arterburn, M. Barton, E.R. Prossnitz.
Science Signaling 9, ra105, 2016
Estrogens and coronary artery disease: new clinical perspectives
M.R. Meyer, M. Barton
Adv Pharmacol 77, 307-360, 2016
GPER is required for the age-dependent upregulation of the myocardial endothelin system
M.R. Meyer, N.C. Fredette, G. Sharma, M. Barton, E.R. Prossnitz
Life Sci 159, 61-65, 2016
Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy
M. Barton, M. Husmann, M.R. Meyer
Can J Cardiol 32, 680-686, 2016
G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
J Endocrinol 227, 61-69, 2015
Prostanoid-mediated contractions of the carotid artery become Nox2-independent with aging
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
AGE 37, 79, 2015
Aging and endothelin: determinants of disease
M. Barton
Life Sci 118, 97-109, 2014
Advancing and translating knowledge in vascular medicine
M. Husmann, M. Barton
Front Cardiovasc Med 1, 6, 2014
Endothelin-1 but not angiotensin II contributes to functional aging in murine carotid arteries
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
Life Sci 118, 213-218, 2014
Functional heterogenity of NADPH oxidase-mediated contractions to endothelin with vascular aging
M.R. Meyer, M. Barton, E.R Prossnitz
Life Sci 118, 226-231, 2014
Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013
The G protein-coupled estrogen receptor GPER in physiology and disease
E.R. Prossnitz, M. Barton
Nature Rev Endocrinol 7, 715-726, 2011
Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis
M. Barton
Pflügers Arch 460, 825-837, 2010
Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans
M. Barton
Biochim Biophys Acta 1802, 1203-1213, 2010
Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780
M.R. Meyer, O. Baretella, E.R. Prossnitz, M. Barton
Pharmacology 86, 58-64, 2010
Lung cancer and hormone replacement therapy
M. Barton, M.R. Meyer, J.L. Bolton, E.R. Prossnitz
Lancet 375, 117-118, 2010
Postmenopausal hypertension: Mechanisms and therapy
M. Barton, M.R. Meyer
Hypertension 54, 11-18, 2009
Curriculum: Artériopathies athérosclérotique et monoxyde d’azote (NO) : l’importance clinique d’une espérance de vie plus longue et l’obésité
M. Husmann, M. Keller, M. Barton
Forum Médical Suisse 50, 1008-1011, 2007
Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?
M. Barton, M.R. Meyer, E. Haas
Arterioscler Thromb Vasc Biol 27, 1669-1672, 2007
WISDOM trial, postmenopausal hormone replacement and cardiovascular events: Why it is still not wise to use equine estrogens
M. Barton, M.R.Meyer, I. Bhattacharya, E. Haas
Br Med J e-pub, rapid response August 28, 2007
Atherosklerotische Gefässerkrankungen und Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher Lebenserwartung
und Übergewicht für die Klinik
M. Husmann, M. Keller, M. Barton
Swiss Medical Forum 50, 1008-1011, 2007
Curriculum: Atherosklerotische Gefässerkrankungen und Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher Lebenserwartung und Übergewicht für die Klinik
M. Husmann, M. Keller, M. Barton
Swiss Medical Forum 50, 1008-1011, 2007
Aging and biomedicine 2005: Where should we go from here?
M. Barton
Cardiovasc Res 66, 187-189, 2005
Anatomically distinct activation of endothelin-3 and the L-arginine/nitric oxide pathway in the kidney with advanced aging
T. Lattmann, S. Shaw, K. Münter, W. Vetter, M. Barton
Biochem Biophys Res Commun 327, 234-241, 2005
Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen
R.K. Dubey, B. Imthurn, M. Barton, E.K. Jackson
Cardiovasc Res 66 , 295- 306, 2005
Ageing as a determinant of renal and vascular disease: role of endothelial factors
M. Barton
Nephrol Dial Transplant 20, 485-490, 2005
Spotlight issue on cardiovascular aging
S. Pepe, E. Lakatta, M. Barton (Eds).
Cardiovasc Res 66 , 1-419, 2005
Einfluss Postmenopausaler Hormonsubstitution mit konjugierten equinen Oestrogenen und Medroxyprogesteronazetat auf das kardiovaskuläre Risiko
J. Ortmann, W. Vetter, T. Traupe, M. Barton
Schweiz Rundsch Med Prax 93, 904-914, 2004
Postmenopausal hormone-replacement therapy
M. Barton, R.K. Dubey
N Engl J Med 346, 63-65, 2002
Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo. Implications for atherosclerosis
W. Goettsch, T. Lattmann, K. Amann, M. Szibor, H. Morawietz, K. Münter, S.P. Müller, S. Shaw, M. Barton
Biochem Biophys Res Commun 280, 908-13, 2001
Postmenopausal estrogen replacement therapy and atherosclerosis: Can current compounds provide cardiovascular protection?
M. Barton
Exp Opin Invest Drugs 20, 789-809, 2001
Oestrogensubstitutionstherapie und Arteriosklerose - Pathophysiologie und therapeutische Implikationen
M. Barton
J Menopause 7, 12-15, 2000
Endothelial aging. A determinant of cardiovascular risk
M. Barton
In: Cardiovascular Aging. Physiology, Physiology, Pharmacology and Therapeutics. IUPHAR Satellite Symposium, Nancy, France, July 23-24, 1998
Cardiovasc Drug Rev 3, 300-311, 1998
Anatomic heterogeneity of vascular aging. Role of nitric oxide and endothelin
M. Barton, F. Cosentino, R.P. Brandes, P. Moreau, S. Shaw, T.F. Luscher
Hypertension 30, 817-824, 1997
Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery
M.R. Tschudi, M. Barton, N.A. Bersinger, P. Moreau, F. Cosentino, G. Noll, T. Malinski, T.F. Luscher
J Clin Invest 98, 899-905, 1996
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
G.P. Rossi, V. Sanga, M. Barton
eLife 2020;9:e57278
Heart failure with preserved ejection fraction in women - new clues to causes and treatment
M. Barton, M.R. Meyer
JACC Basic Transl Sci 5, 296-299,2020
Endothelin: 30 years from discovery to therapy
M. Barton, M. Yanagisawa
Hypertension 74, 1232-1265, 2019
Nox1 downreglators: A new class of therapeutics
M. Barton, M.R. Meyer, E.R. Prossnitz
Steroids 152, 108949, 2019
Potential role for Nox1 for endothelin-induced brain capillary vasoconstriction in Alzheimer's disease and dementia
M. Barton, M.R. Meyer, E.R. Prossnitz.
Science eaav9518, 2019
Primum non nocere: Why calcitriol («vitamin» D) hormone therapy is not a magic bullet
M. Barton
Arterioscler Thromb Vasc Biol 39, 117-120, 2019
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: role in disease conditions. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 462-471, 2018
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: general mechanisms. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertension 36, 451-461, 2018
GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases
M.R. Meyer, M. Barton
J Steroid Biochem Mol Biol 176, 82-87, 2018
GPER mediates functional endothelial aging in renal arteries
M.R. Meyer, T. Rosemann, M. Barton, E.R. Prossnitz.
Pharmacology 100, 188-193, 2017
Obligatory role for GPER in cardiovascular aging and disease
M.R. Meyer, N.C. Fredette, C. Daniel, G. Sharma, K. Amann, J.B. Arterburn, M. Barton, E.R. Prossnitz.
Science Signaling 9, ra105, 2016
Estrogens and coronary artery disease: new clinical perspectives
M.R. Meyer, M. Barton
Adv Pharmacol 77, 307-360, 2016
GPER is required for the age-dependent upregulation of the myocardial endothelin system
M.R. Meyer, N.C. Fredette, G. Sharma, M. Barton, E.R. Prossnitz
Life Sci 159, 61-65, 2016
Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy
M. Barton, M. Husmann, M.R. Meyer
Can J Cardiol 32, 680-686, 2016
G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
J Endocrinol 227, 61-69, 2015
Prostanoid-mediated contractions of the carotid artery become Nox2-independent with aging
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
AGE 37, 79, 2015
Aging and endothelin: determinants of disease
M. Barton
Life Sci 118, 97-109, 2014
Advancing and translating knowledge in vascular medicine
M. Husmann, M. Barton
Front Cardiovasc Med 1, 6, 2014
Endothelin-1 but not angiotensin II contributes to functional aging in murine carotid arteries
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
Life Sci 118, 213-218, 2014
Functional heterogenity of NADPH oxidase-mediated contractions to endothelin with vascular aging
M.R. Meyer, M. Barton, E.R Prossnitz
Life Sci 118, 226-231, 2014
Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013
The G protein-coupled estrogen receptor GPER in physiology and disease
E.R. Prossnitz, M. Barton
Nature Rev Endocrinol 7, 715-726, 2011
Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis
M. Barton
Pflügers Arch 460, 825-837, 2010
Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans
M. Barton
Biochim Biophys Acta 1802, 1203-1213, 2010
Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780
M.R. Meyer, O. Baretella, E.R. Prossnitz, M. Barton
Pharmacology 86, 58-64, 2010
Lung cancer and hormone replacement therapy
M. Barton, M.R. Meyer, J.L. Bolton, E.R. Prossnitz
Lancet 375, 117-118, 2010
Postmenopausal hypertension: Mechanisms and therapy
M. Barton, M.R. Meyer
Hypertension 54, 11-18, 2009
Curriculum: Artériopathies athérosclérotique et monoxyde d’azote (NO) : l’importance clinique d’une espérance de vie plus longue et l’obésité
M. Husmann, M. Keller, M. Barton
Forum Médical Suisse 50, 1008-1011, 2007
Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?
M. Barton, M.R. Meyer, E. Haas
Arterioscler Thromb Vasc Biol 27, 1669-1672, 2007
WISDOM trial, postmenopausal hormone replacement and cardiovascular events: Why it is still not wise to use equine estrogens
M. Barton, M.R.Meyer, I. Bhattacharya, E. Haas
Br Med J e-pub, rapid response August 28, 2007
Atherosklerotische Gefässerkrankungen und Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher Lebenserwartung
und Übergewicht für die Klinik
M. Husmann, M. Keller, M. Barton
Swiss Medical Forum 50, 1008-1011, 2007
Curriculum: Atherosklerotische Gefässerkrankungen und Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher Lebenserwartung und Übergewicht für die Klinik
M. Husmann, M. Keller, M. Barton
Swiss Medical Forum 50, 1008-1011, 2007
Aging and biomedicine 2005: Where should we go from here?
M. Barton
Cardiovasc Res 66, 187-189, 2005
Anatomically distinct activation of endothelin-3 and the L-arginine/nitric oxide pathway in the kidney with advanced aging
T. Lattmann, S. Shaw, K. Münter, W. Vetter, M. Barton
Biochem Biophys Res Commun 327, 234-241, 2005
Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen
R.K. Dubey, B. Imthurn, M. Barton, E.K. Jackson
Cardiovasc Res 66 , 295- 306, 2005
Ageing as a determinant of renal and vascular disease: role of endothelial factors
M. Barton
Nephrol Dial Transplant 20, 485-490, 2005
Spotlight issue on cardiovascular aging
S. Pepe, E. Lakatta, M. Barton (Eds).
Cardiovasc Res 66 , 1-419, 2005
Einfluss Postmenopausaler Hormonsubstitution mit konjugierten equinen Oestrogenen und Medroxyprogesteronazetat auf das kardiovaskuläre Risiko
J. Ortmann, W. Vetter, T. Traupe, M. Barton
Schweiz Rundsch Med Prax 93, 904-914, 2004
Postmenopausal hormone-replacement therapy
M. Barton, R.K. Dubey
N Engl J Med 346, 63-65, 2002
Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo. Implications for atherosclerosis
W. Goettsch, T. Lattmann, K. Amann, M. Szibor, H. Morawietz, K. Münter, S.P. Müller, S. Shaw, M. Barton
Biochem Biophys Res Commun 280, 908-13, 2001
Postmenopausal estrogen replacement therapy and atherosclerosis: Can current compounds provide cardiovascular protection?
M. Barton
Exp Opin Invest Drugs 20, 789-809, 2001
Oestrogensubstitutionstherapie und Arteriosklerose - Pathophysiologie und therapeutische Implikationen
M. Barton
J Menopause 7, 12-15, 2000
Endothelial aging. A determinant of cardiovascular risk
M. Barton
In: Cardiovascular Aging. Physiology, Physiology, Pharmacology and Therapeutics. IUPHAR Satellite Symposium, Nancy, France, July 23-24, 1998
Cardiovasc Drug Rev 3, 300-311, 1998
Anatomic heterogeneity of vascular aging. Role of nitric oxide and endothelin
M. Barton, F. Cosentino, R.P. Brandes, P. Moreau, S. Shaw, T.F. Luscher
Hypertension 30, 817-824, 1997
Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery
M.R. Tschudi, M. Barton, N.A. Bersinger, P. Moreau, F. Cosentino, G. Noll, T. Malinski, T.F. Luscher
J Clin Invest 98, 899-905, 1996